drug_type
RELEVANT_DRUG
intervention_type
Biologic immunotherapy
drug_description
An intravenous CD19-directed, T-cell–redirecting biologic immunotherapy given with step-up dosing; binds CD19 on B cells to engage and activate T cells for cytotoxic killing of malignant B cells, with expected on-target depletion of normal CD19+ B cells. Studied in CD19+ B-cell malignancies (B-NHL, B-ALL, CLL).
nci_thesaurus_concept_id
C201656
nci_thesaurus_definition
A trispecific T-cell engager and antibody targeting the tumor-associated antigen (TAA) CD19, the T-cell surface antigen CD3, and the T-cell specific surface glycoprotein and co-stimulatory molecule CD28, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD19/anti-CD3/anti-CD28 trispecific antibody CC312 targets and binds to CD3 and CD28 on T-cells and CD19 expressed on tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies.
drug_category
TRISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Intravenous
drug_mechanism_of_action
A trispecific T-cell engager antibody that binds CD19 on B cells and CD3/CD28 on T cells to crosslink and costimulate T cells, redirecting cytotoxic activity against CD19+ malignant B cells; on-target depletion of normal CD19+ B cells is expected.
drug_name
CC312
nct_id_drug_ref
NCT06037018